Beatriz Silva Lima

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7617391/publications.pdf

Version: 2024-02-01

32 papers 1,759 citations

361296 20 h-index 35 g-index

38 all docs 38 docs citations

38 times ranked 2755 citing authors

#	Article	IF	Citations
1	Renal biomarker qualification submission: a dialog between the FDA-EMEA and Predictive Safety Testing Consortium. Nature Biotechnology, 2010, 28, 455-462.	9.4	355
2	Antiâ€inflammatory Effect of Rosmarinic Acid and an Extract of ⟨i⟩Rosmarinus officinalis⟨i⟩ in Rat Models of Local and Systemic Inflammation. Basic and Clinical Pharmacology and Toxicology, 2015, 116, 398-413.	1.2	193
3	Challenges with advanced therapy medicinal products and how to meet them. Nature Reviews Drug Discovery, 2010, 9, 195-201.	21.5	191
4	Next-generation nanomedicines and nanosimilars: EU regulators' initiatives relating to the development and evaluation of nanomedicines. Nanomedicine, 2013, 8, 849-856.	1.7	122
5	Towards consensus practices to qualify safety biomarkers for use in early drug development. Nature Biotechnology, 2010, 28, 446-454.	9.4	113
6	Immunogenicity of mAbs in non-human primates during nonclinical safety assessment. MAbs, 2013, 5, 810-816.	2.6	104
7	Applying 'omics technologies in chemicals risk assessment: Report of an ECETOC workshop. Regulatory Toxicology and Pharmacology, 2017, 91, S3-S13.	1.3	102
8	Mechanisms of Nongenotoxic Carcinogenesis and Assessment of the Human Hazard. Regulatory Toxicology and Pharmacology, 2000, 32, 135-143.	1.3	90
9	Stem cell–derived models to improve mechanistic understanding and prediction of human drugâ€induced liver injury. Hepatology, 2017, 65, 710-721.	3.6	54
10	Evading P-glycoprotein mediated-efflux chemoresistance using Solid Lipid Nanoparticles. European Journal of Pharmaceutics and Biopharmaceutics, 2017, 110, 76-84.	2.0	46
11	Scientific considerations for complex drugs in light of established and emerging regulatory guidance. Annals of the New York Academy of Sciences, 2012, 1276, 26-36.	1.8	32
12	Critical analysis of carcinogenicity study outcomes. Relationship with pharmacological properties. Critical Reviews in Toxicology, 2016, 46, 587-614.	1.9	30
13	Oral supplementation with fish oil reduces dryness and pruritus in the acetone-induced dry skin rat model. Journal of Dermatological Science, 2015, 79, 298-304.	1.0	28
14	White Paper on How to Go Forward with Cell-Based Advanced Therapies in Europe. Tissue Engineering - Part A, 2014, 20, 2549-2554.	1.6	27
15	Regulatory acceptance of animal models of disease to support clinical trials of medicines and advanced therapy medicinal products. European Journal of Pharmacology, 2015, 759, 51-62.	1.7	24
16	Total phenolic content, antioxidant activity and pre-clinical safety evaluation of an Anacardium occidentale stem bark Portuguese hypoglycemic traditional herbal preparation. Industrial Crops and Products, 2016, 82, 171-178.	2.5	23
17	Recommendations from a global cross-company data sharing initiative on the incorporation of recovery phase animals in safety assessment studies to support first-in-human clinical trials. Regulatory Toxicology and Pharmacology, 2014, 70, 413-429.	1.3	22
18	Contribution of animal studies to evaluate the similarity of biosimilars to reference products. Drug Discovery Today, 2015, 20, 483-490.	3.2	22

#	Article	IF	CITATIONS
19	Value of juvenile animal studies. Birth Defects Research Part B: Developmental and Reproductive Toxicology, 2011, 92, 292-303.	1.4	20
20	Effect of a Supplemented Diet with Canned Sardine on the Lipid Fraction of Human Plasma and Erythrocytes. Journal of Aquatic Food Product Technology, 2002, 11, 177-185.	0.6	14
21	Insights on the safety of carotenogenic Chlorella vulgaris in rodents. Algal Research, 2013, 2, 409-415.	2.4	14
22	Chronic Hyperglycemia Modulates Rat Osteoporotic Cortical Bone Microarchitecture into Less Fragile Structures. International Journal of Endocrinology, 2017, 2017, 1-9.	0.6	9
23	Carcinogenicity Testing of Pharmaceuticals in the European Union: A Workshop Report. Drug Information Journal, 2000, 34, 821-828.	0.5	8
24	The regulator's perspective: How should new therapies and follow-on products for MS be clinically evaluated in the future?. Multiple Sclerosis Journal, 2016, 22, 47-59.	1.4	8
25	Evaluation of Marine Microalga Diacronema vlkianum Biomass Fatty Acid Assimilation in Wistar Rats. Molecules, 2017, 22, 1097.	1.7	8
26	Alternatives Models in Carcinogenicity Testingâ€"A European Perspective. Toxicologic Pathology, 2002, 30, 157-159.	0.9	7
27	Juvenile animal studies in the development of pediatric medicines: experience from European medicines and pediatric investigation plans. Birth Defects Research Part B: Developmental and Reproductive Toxicology, 2011, 92, n/a-n/a.	1.4	5
28	Nitric Oxide Synthase/Guanylate Cyclase Pathway Modulates the Rat Vas Deferens Contractility Induced by Phenylephrine. Basic and Clinical Pharmacology and Toxicology, 2002, 91, 179-184.	0.0	3
29	Supplementation of the Diet of Haemodialysis Patients with Portuguese Canned Sardines and Evaluation of I‰3 Fatty Acid Level in Erythrocyte Phospholipids. Journal of Aquatic Food Product Technology, 2004, 13, 61-68.	0.6	3
30	The European and American Use of Exploratory Approaches for First-in-Human Studies. Clinical and Translational Science, 2010, 3, 38-41.	1.5	2
31	Phenylephrine Induces Endogenous Noradrenaline Release in the Rat Vas deferens through Nitric Oxide Synthase Pathway. Basic and Clinical Pharmacology and Toxicology, 2003, 93, 191-196.	0.0	1
32	Sales of antibiotics for veterinary use in Portugal between 2006 and 2009. International Journal of Antimicrobial Agents, 2014, 44, 567-568.	1.1	1